

Charles S Fuchs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938953/publications.pdf>

Version: 2024-02-01

250
papers

26,988
citations

11235

73
h-index

7627

156
g-index

254
all docs

254
docs citations

254
times ranked

33851
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
2	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	3.0	24
3	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	0.8	20
4	Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. <i>Cancer Prevention Research</i> , 2022, 15, 265-272.	0.7	7
5	Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates. <i>Mayo Clinic Proceedings</i> , 2022, 97, 124-133.	1.4	3
6	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505.	1.9	5
7	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	1.9	2
8	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	0.5	3
9	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 101-101.	0.8	0
10	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. <i>JAMA Network Open</i> , 2022, 5, e220145.	2.8	3
11	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
12	Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 215-227.	1.6	23
13	Myths about diversity in clinical trials reduce return on investment for industry. <i>Nature Medicine</i> , 2022, 28, 1520-1522.	15.2	6
14	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	3.2	35
15	No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 128-135.e6.	2.4	28
16	Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa089.	1.4	11
17	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa074.	1.4	6
18	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	1.1	117

#	ARTICLE	IF	CITATIONS
19	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1069-1081.	3.2	75
20	Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1612-1624.	2.2	9
21	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10 . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	3.2	53
22	Preexisting Type 2 Diabetes and Survival among Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 757-764.	1.1	6
23	Dairy consumption, plasma metabolites, and risk of type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 163-174.	2.2	29
24	Prediagnostic Inflammation and Pancreatic Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1186-1193.	3.0	9
25	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	3.8	63
26	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	1.4	4
27	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3568-3568.	0.8	0
28	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3588-3588.	0.8	0
29	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. <i>JAMA Network Open</i> , 2021, 4, e2112539.	2.8	48
30	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	0.7	2
31	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	3.4	184
32	Discovery and Features of an Alkylating Signature in Colorectal Cancer. <i>Cancer Discovery</i> , 2021, 11, 2446-2455.	7.7	42
33	Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. <i>Cancer Research</i> , 2021, 81, CT167-CT167.	0.4	11
34	Simple Sugar and Sugar-Sweetened Beverage Intake During Adolescence and Risk of Colorectal Cancer Precursors. <i>Gastroenterology</i> , 2021, 161, 128-142.e20.	0.6	58
35	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1408-1417.	2.2	9
36	Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	2.7	7
38	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2021, 17, 2847-2855.	1.1	33
39	Unrestrained eating behavior and risk of mortality: A prospective cohort study. <i>Clinical Nutrition</i> , 2021, 40, 5419-5429.	2.3	5
40	Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors. <i>Gastroenterology</i> , 2021, 161, 1208-1217.e9.	0.6	40
41	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	0.8	0
42	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. <i>JAMA Network Open</i> , 2021, 4, e2139593.	2.8	55
43	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz078.	1.4	22
44	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	3.0	59
45	Endogenous sex hormones and colorectal cancer survival among men and women. <i>International Journal of Cancer</i> , 2020, 147, 920-930.	2.3	17
46	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	1.4	8
47	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. <i>EBioMedicine</i> , 2020, 57, 102860.	2.7	31
48	Diabetes, Weight Change, and Pancreatic Cancer Risk. <i>JAMA Oncology</i> , 2020, 6, e202948.	3.4	72
49	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	3.4	611
50	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1713.	3.4	24
51	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	0.7	17
52	Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients. <i>BMC Cancer</i> , 2020, 20, 817.	1.1	16
53	Prediagnostic Circulating Concentrations of Vitamin D Binding Protein and Survival among Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2323-2331.	1.1	9
54	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500.	2.8	8

#	ARTICLE	IF	CITATIONS
55	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 999-1008.	1.1	19
56	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1586-1595.	1.1	8
57	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1692-1695.	1.1	5
58	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	1.4	14
59	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2020, 181, 832-847.e18.	13.5	77
60	Dietary Intake of Branched-Chain Amino Acids and Risk of Colorectal Cancer. <i>Cancer Prevention Research</i> , 2020, 13, 65-72.	0.7	12
61	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3089-3089.	0.8	3
62	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4003-4003.	0.8	2
63	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€œpositive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4503-4503.	0.8	31
64	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4512-4512.	0.8	26
65	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	0.8	38
66	Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1â€œpositive (CPS â‰¥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 427-427.	0.8	13
67	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	0.8	20
68	How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 89-89.	0.8	1
69	A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS460-TPS460.	0.8	3
70	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS463-TPS463.	0.8	4
71	Long-term cancer survival in cohorts of U.S. health professionals.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12075-12075.	0.8	0
72	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 146-157.	3.0	129

#	ARTICLE	IF	CITATIONS
73	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019, 111, 170-179.	3.0	19
74	Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2019, 37, 159-165.	1.2	28
75	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019, 37, 2620-2631.	0.8	51
76	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JPDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
77	Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. <i>Journal of Nutrition</i> , 2019, 149, 1215-1221.	1.3	11
78	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019, 25, 7497-7505.	3.2	44
79	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
80	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	3.2	26
81	Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II. <i>British Journal of Cancer</i> , 2019, 121, 86-94.	2.9	19
82	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019, 30, 757-765.	0.8	4
83	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019, 111, 82-93.	1.3	17
84	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	2.0	14
85	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
86	Calcium Intake and Risk of Colorectal Cancer According to Tumor-infiltrating T Cells. <i>Cancer Prevention Research</i> , 2019, 12, 283-294.	0.7	11
87	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019, 15, 943-952.	1.1	133
88	Fish and marine fatty acids intakes, the FADS genotypes and long-term weight gain: a prospective cohort study. <i>BMJ Open</i> , 2019, 9, e022877.	0.8	5
89	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 1494-1505.	7.0	83
90	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 557-567.	3.0	21

#	ARTICLE	IF	CITATIONS
91	Calcium Intake and Survival after Colorectal Cancer Diagnosis. <i>Clinical Cancer Research</i> , 2019, 25, 1980-1988.	3.2	20
92	Inherited DNA-Repair Defects in Colorectal Cancer. <i>American Journal of Human Genetics</i> , 2018, 102, 401-414.	2.6	89
93	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	7.7	367
94	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1300-1306.e3.	2.4	21
95	Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. <i>International Journal of Cancer</i> , 2018, 143, 1047-1053.	2.3	22
96	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. <i>JAMA Oncology</i> , 2018, 4, 783.	3.4	147
97	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
98	Marine ω -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	1.1	52
99	Association Between Coffee Intake After Diagnosis of Colorectal Cancer and Reduced Mortality. <i>Gastroenterology</i> , 2018, 154, 916-926.e9.	0.6	52
100	Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain <i>Fusobacterium nucleatum</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1622-1631.e3.	2.4	103
101	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
102	Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). <i>Gut</i> , 2018, 67, 1475-1483.	6.1	39
103	Social integration and survival after diagnosis of colorectal cancer. <i>Cancer</i> , 2018, 124, 833-840.	2.0	29
104	Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. <i>Journal of Oncology Practice</i> , 2018, 14, e823-e833.	2.5	11
105	Reply to L. Fornaro et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1179-1180.	0.8	0
106	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	0.8	50
107	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. <i>Genome Biology</i> , 2018, 19, 142.	3.8	20
108	The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. <i>American Journal of Pathology</i> , 2018, 188, 2839-2852.	1.9	51

#	ARTICLE	IF	CITATIONS
109	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectrum, 2018, 2, pky017.	1.4	10
110	Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. European Journal of Cancer, 2018, 103, 98-107.	1.3	21
111	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS ONE, 2018, 13, e0199244.	1.1	25
112	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
113	Association of dietary insulinemic potential and colorectal cancer risk in men and women. American Journal of Clinical Nutrition, 2018, 108, 363-370.	2.2	57
114	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis.. Journal of Clinical Oncology, 2018, 36, 723-723.	0.8	1
115	Body Mass Index and Other Anthropomorphic Variables in Relation to Risk of Colorectal Carcinoma Subtypes Classified by Tumor Differentiation Status. FASEB Journal, 2018, 32, 677.9.	0.2	0
116	Tumor Nuclear <i>YAP1</i> Expression Status and Molecular Characteristics in relation to Immune Response to Colorectal Carcinoma. FASEB Journal, 2018, 32, 406.5.	0.2	0
117	Multiplexed Immuno-profiling of the Colorectal Carcinoma Microenvironment Using Archival Human Tissue. FASEB Journal, 2018, 32, 818.4.	0.2	0
118	Bifidobacterium Genus in Colorectal Carcinoma Tissue in relation to Tumor Characteristics and Patient Survival. FASEB Journal, 2018, 32, 407.3.	0.2	0
119	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. Journal of Clinical Oncology, 2018, 36, 4044-4044.	0.8	1
120	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	0.8	383
121	A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers. American Journal of Gastroenterology, 2017, 112, 493-501.	0.2	17
122	Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. International Journal of Cancer, 2017, 140, 2648-2656.	2.3	17
123	Marine ω -3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. Gut, 2017, 66, 1790-1796.	6.1	89
124	Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. Gastroenterology, 2017, 152, 1944-1953.e1.	0.6	124
125	Leucocyte telomere length, genetic variants at the <i>TERT</i> gene region and risk of pancreatic cancer. Gut, 2017, 66, 1116-1122.	6.1	39
126	Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology, 2017, 6, e1284720.	2.1	18

#	ARTICLE	IF	CITATIONS
127	Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. <i>European Journal of Epidemiology</i> , 2017, 32, 419-430.	2.5	17
128	Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. <i>Gastroenterology</i> , 2017, 153, 1517-1530.e14.	0.6	62
129	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	6.0	983
130	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	3.2	44
131	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. <i>Oncologist</i> , 2017, 22, 107-114.	1.9	18
132	Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by <i>Fusobacterium nucleatum</i> in Tumor Tissue. <i>JAMA Oncology</i> , 2017, 3, 921.	3.4	243
133	Development and Validation of the PREMM ₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 2165-2172.	0.8	126
134	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	0.8	112
135	Cigarette Smoking and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2017, 35, 1822-1828.	0.8	78
136	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.8	110
137	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
138	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10059-10059.	0.8	1
139	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	0.8	134
140	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4046-4046.	0.8	14
141	Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15000-e15000.	0.8	0
142	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	0.8	88
143	Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study. <i>Cancer Prevention Research</i> , 2016, 9, 664-672.	0.7	38
144	Development and Validation of an Empirical Dietary Inflammatory Index. <i>Journal of Nutrition</i> , 2016, 146, 1560-1570.	1.3	263

#	ARTICLE	IF	CITATIONS
145	Development and validation of empirical indices to assess the insulinaemic potential of diet and lifestyle. <i>British Journal of Nutrition</i> , 2016, 116, 1787-1798.	1.2	91
146	Association of Physical Activity by Type and Intensity With Digestive System Cancer Risk. <i>JAMA Oncology</i> , 2016, 2, 1146.	3.4	78
147	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1185-1191.	1.1	29
148	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 995-1002.	2.9	31
149	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , 2016, 15, 857-865.	2.9	671
150	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , 2016, 115, 974-982.	2.9	53
151	Associations between nut consumption and inflammatory biomarkers,. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 722-728.	2.2	80
152	Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study. <i>International Journal of Cancer</i> , 2016, 139, 1949-1957.	2.3	33
153	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. <i>Cancer Research</i> , 2016, 76, 7160-7167.	0.4	46
154	Nut consumption and prostate cancer risk and mortality. <i>British Journal of Cancer</i> , 2016, 115, 371-374.	2.9	24
155	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 2899-2905.	0.8	49
156	Sedentary behaviors and light-intensity activities in relation to colorectal cancer risk. <i>International Journal of Cancer</i> , 2016, 138, 2109-2117.	2.3	23
157	CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. <i>British Journal of Cancer</i> , 2016, 114, 221-229.	2.9	18
158	Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women. <i>Cancer Prevention Research</i> , 2016, 9, 27-34.	0.7	30
159	Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 497-504.	2.0	156
160	Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. <i>Nature Genetics</i> , 2016, 48, 189-194.	9.4	211
161	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. <i>Carcinogenesis</i> , 2016, 37, 87-95.	1.3	62
162	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv363.	3.0	37

#	ARTICLE	IF	CITATIONS
163	Long-term status and change of body fat distribution, and risk of colorectal cancer: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2016, 45, 871-883.	0.9	52
164	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116
165	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1489-1498.	3.2	9
166	Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4-4.	0.8	17
167	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS178-TPS178.	0.8	2
168	Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	0.8	0
169	Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. <i>Scientific Reports</i> , 2015, 5, 10411.	1.6	7
170	Reduction of parathyroid hormone with vitamin D supplementation in blacks: a randomized controlled trial. <i>BMC Nutrition</i> , 2015, 1, .	0.6	3
171	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
172	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
173	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. <i>Gastroenterology</i> , 2015, 149, 614-622.	0.6	44
174	<i>Fusobacterium nucleatum</i> and T Cells in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 653.	3.4	498
175	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	2.6	101
176	LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. <i>Genes and Development</i> , 2015, 29, 1074-1086.	2.7	92
177	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv150-djv150.	3.0	0
178	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. <i>Journal of Clinical Oncology</i> , 2015, 33, 29-35.	0.8	83
179	Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. <i>Modern Pathology</i> , 2015, 28, 14-29.	2.9	172
180	Red Meat Intake, NAT2, and Risk of Colorectal Cancer: A Pooled Analysis of 11 Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 198-205.	1.1	38

#	ARTICLE	IF	CITATIONS
181	Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1398-1406.	1.1	47
182	Genome-wide association study of colorectal cancer identifies six new susceptibility loci. <i>Nature Communications</i> , 2015, 6, 7138.	5.8	138
183	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2015, 47, 911-916.	9.4	224
184	Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses' Health Study and Health Professionals Follow-up Study. <i>Cancer Prevention Research</i> , 2015, 8, 620-627.	0.7	31
185	Early Life Body Fatness and Risk of Colorectal Cancer in U.S. Women and Men—Results from Two Large Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 690-697.	1.1	74
186	Marine ω -3 Polyunsaturated Fatty Acids and Risk for Colorectal Cancer According to Microsatellite Instability. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	37
187	Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1133.	3.8	171
188	Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. <i>Carcinogenesis</i> , 2015, 36, 999-1007.	1.3	28
189	Oral Contraceptive Use and Colorectal Cancer in the Nurses' Health Study I and II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1214-1221.	1.1	16
190	Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. <i>Cancer Prevention Research</i> , 2015, 8, 1138-1145.	0.7	23
191	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	0.8	60
192	Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy. <i>Radiographics</i> , 2015, 35, 2090-2107.	1.4	42
193	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 345.	3.0	115
194	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
195	Joint Effects of Colorectal Cancer Susceptibility Loci, Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e92212.	1.1	12
196	Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women. <i>PLoS ONE</i> , 2014, 9, e115377.	1.1	74
197	Predicted 25(OH)D Score and Colorectal Cancer Risk According to Vitamin D Receptor Expression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1628-1637.	1.1	23
198	Gene-Environment Interaction Involving Recently Identified Colorectal Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1824-1833.	1.1	48

#	ARTICLE	IF	CITATIONS
199	Null Association between Vitamin D and PSA Levels among Black Men in a Vitamin D Supplementation Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1944-1947.	1.1	22
200	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	1.9	292
201	Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. <i>International Journal of Cancer</i> , 2014, 134, 2458-2467.	2.3	46
202	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
203	Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 1479-1488.	2.2	27
204	Response. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju181-dju181.	3.0	0
205	Urinary PGE-M Levels Are Associated with Risk of Colorectal Adenomas and Chemopreventive Response to Anti-Inflammatory Drugs. <i>Cancer Prevention Research</i> , 2014, 7, 758-765.	0.7	36
206	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	58
207	Plasma 25-Hydroxyvitamin D and Risk of Colorectal Cancer after Adjusting for Inflammatory Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2175-2180.	1.1	16
208	Risk of Hypercalcemia in Blacks Taking Hydrochlorothiazide and Vitamin D. <i>American Journal of Medicine</i> , 2014, 127, 772-778.	0.6	10
209	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2014, 383, 31-39.	6.3	1,833
210	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , 2014, 46, 1264-1266.	9.4	388
211	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	28
212	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
213	Progress and Opportunities in Molecular Pathological Epidemiology of Colorectal Premalignant Lesions. <i>American Journal of Gastroenterology</i> , 2014, 109, 1205-1214.	0.2	55
214	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1879-1886.	2.4	76
215	Aspirin, the new targeted therapy in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 186-9.	0.3	0
216	Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2563.	3.8	146

#	ARTICLE	IF	CITATIONS
217	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013, 12, 233-238.	1.0	31
218	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	1.0	17
219	A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification. <i>American Journal of Epidemiology</i> , 2013, 178, 84-100.	1.6	81
220	Physical Activity, Tumor PTGS2 Expression, and Survival in Patients with Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1142-1152.	1.1	34
221	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	3.0	163
222	The Joint Association of Eating Frequency and Diet Quality With Colorectal Cancer Risk in the Health Professionals Follow-up Study. <i>American Journal of Epidemiology</i> , 2012, 175, 664-672.	1.6	14
223	Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, 1199-1206.	0.6	101
224	Reported behavior of eating anything at anytime and risk of colorectal cancer in women. <i>International Journal of Cancer</i> , 2012, 130, 1395-1400.	2.3	4
225	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	9.4	270
226	Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. <i>Gut</i> , 2011, 60, 397-411.	6.1	453
227	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. <i>Nature Genetics</i> , 2010, 42, 224-228.	9.4	539
228	Aspirin Use and Survival After Diagnosis of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 649.	3.8	497
229	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	0.8	208
230	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. <i>Nature Genetics</i> , 2009, 41, 986-990.	9.4	597
231	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	0.8	245
232	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	3.2	52
233	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	3.8	369
234	Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. <i>New England Journal of Medicine</i> , 2007, 356, 2131-2142.	13.9	692

#	ARTICLE	IF	CITATIONS
235	IGFBP3 Promoter Methylation in Colorectal Cancer: Relationship with Microsatellite Instability, CpG Island Methylator Phenotype, p53. <i>Neoplasia</i> , 2007, 9, 1091-1098.	2.3	34
236	Evaluation of Markers for CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer by a Large Population-Based Sample. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 305-314.	1.2	296
237	Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 209-217.	1.2	361
238	Physical Activity and Survival After Colorectal Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 3527-3534.	0.8	762
239	Irinotecan in the treatment of colorectal cancer. <i>Cancer Treatment Reviews</i> , 2006, 32, 491-503.	3.4	148
240	Cancer of the Appendix. , 2006, , 410-417.		0
241	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006, 24, 3535-3541.	0.8	664
242	Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men. <i>Journal of the National Cancer Institute</i> , 2006, 98, 451-459.	3.0	922
243	Dietary Patterns and Pancreatic Cancer Risk in Men and Women. <i>Journal of the National Cancer Institute</i> , 2005, 97, 518-524.	3.0	95
244	Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8453-8460.	0.8	23
245	Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 413-421.	1.2	448
246	Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 138-47.	1.1	52
247	Aspirin Use and Risk for Colorectal Adenoma. <i>Annals of Internal Medicine</i> , 2004, 141, 406.	2.0	0
248	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. <i>Cancer</i> , 2003, 98, 484-495.	2.0	285
249	A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2002, 94, 3186-3191.	2.0	95
250	Prospective Study of Fruit and Vegetable Consumption and Incidence of Colon and Rectal Cancers. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1740-1752.	3.0	369